Brokerages expect Sanofi SA (NYSE:SNY) to post $0.93 earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Sanofi’s earnings, with the lowest EPS estimate coming in at $0.90 and the highest estimate coming in at $0.96. Sanofi reported earnings of $1.00 per share during the same quarter last year, which indicates a negative year over year growth rate of 7%. The company is expected to issue its next quarterly earnings report before the market opens on Wednesday, October 31st.
According to Zacks, analysts expect that Sanofi will report full-year earnings of $3.15 per share for the current year, with EPS estimates ranging from $3.13 to $3.18. For the next year, analysts expect that the company will report earnings of $3.36 per share, with EPS estimates ranging from $3.32 to $3.41. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Sanofi.
Sanofi (NYSE:SNY) last posted its quarterly earnings data on Tuesday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.02. The company had revenue of $8.18 billion for the quarter, compared to analyst estimates of $8.27 billion. Sanofi had a net margin of 10.29% and a return on equity of 23.77%. The business’s quarterly revenue was down 5.6% on a year-over-year basis. During the same quarter last year, the firm posted $1.35 earnings per share.
A number of analysts have recently issued reports on the stock. Citigroup upgraded shares of Sanofi from a “neutral” rating to a “buy” rating in a research note on Friday, August 10th. ValuEngine lowered shares of Sanofi from a “sell” rating to a “strong sell” rating in a research note on Saturday, June 2nd. Zacks Investment Research upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Wednesday, June 13th. Deutsche Bank restated a “buy” rating on shares of Sanofi in a research note on Wednesday, August 1st. Finally, BNP Paribas upgraded shares of Sanofi from a “neutral” rating to an “outperform” rating in a research note on Wednesday, August 1st. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $47.00.
Shares of SNY traded down $0.05 during mid-day trading on Friday, reaching $42.09. 654,404 shares of the stock traded hands, compared to its average volume of 1,982,120. The firm has a market capitalization of $105.79 billion, a P/E ratio of 13.46, a P/E/G ratio of 2.19 and a beta of 0.85. Sanofi has a 12-month low of $37.43 and a 12-month high of $50.65. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40.
Several large investors have recently modified their holdings of the stock. Private Capital Group LLC boosted its holdings in Sanofi by 271.3% in the first quarter. Private Capital Group LLC now owns 2,577 shares of the company’s stock worth $103,000 after purchasing an additional 1,883 shares during the period. Whittier Trust Co. boosted its holdings in Sanofi by 290.0% in the first quarter. Whittier Trust Co. now owns 3,362 shares of the company’s stock worth $135,000 after purchasing an additional 2,500 shares during the period. Bray Capital Advisors acquired a new position in Sanofi in the first quarter worth $155,000. Squar Milner Financial Services LLC acquired a new position in Sanofi in the second quarter worth $169,000. Finally, IHT Wealth Management LLC boosted its holdings in Sanofi by 246.6% in the first quarter. IHT Wealth Management LLC now owns 4,239 shares of the company’s stock worth $167,000 after purchasing an additional 3,016 shares during the period. Institutional investors and hedge funds own 7.54% of the company’s stock.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an oral immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
See Also: What is a Stop Order?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.